NAMS: Prakiraan pendapatan perusahaan NewAmsterdam Pharma

NAMS (NewAmsterdam Pharma N.V.) - tandha merek perusahaan

NewAmsterdam Pharma (NAMS) relies on the patent protection of its unique class of drugs, which will ensure premium pricing. The innovative drug Obicetrapib replaces costly injections for the treatment of high cholesterol by inhibiting CETP. However, the business's success is tied to a single cardio-metabolic product and the results of clinical trials. The company's sales volume projection on GURU.Markets contains data where the value has settled at 0.03.

Prakiraan pendapatan perusahaan: NewAmsterdam Pharma Corp (NAMS) kanggo 21.06.2023 - 17.11.2026

Rincian analitis lan laporan data perusahaan NewAmsterdam Pharma Corp (NAMS)

Analisis fundamental perusahaan:NAMS NewAmsterdam Pharma N.V.
Produk mawa merek NewAmsterdam Pharma N.V.

The indicator transforms retrospective reporting into a dynamic revenue forecast by aggregating analyst consensus estimates to rapidly determine the asset's fundamental value. By analyzing the firm's sales volume expectations, investors can see the commercialization potential of Obicetrapib, where replacing costly injections with an affordable cholesterol-fighting pill directly determines the future cash flow trajectory of NewAmsterdam Pharma (NAMS).

Karo sapa NewAmsterdam Pharma saingan

Prakiraan volume dodolan ASND|Prakiraan pendapatan perusahaan MDGL (Madrigal Pharmaceuticals Inc)|Prakiraan pendapatan perusahaan corcept.com CORT|Rhythm Corp (RYTM) - Volume dodolan sing dikarepake perusahaan|AKRO - Prakiraan pendapatan perusahaan|MTSR: Prakiraan pendapatan perusahaan|MLTX: Prakiraan volume dodolan|CRNX - Dodolan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Soleno Therapeutics Corp|Amicus Corp (FOLD) - Dodolan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan 89bio.com (ETNB)|Volume dodolan mangsa ngarep perusahaan Agios Pharmaceuticals AGIO|Prakiraan pendapatan perusahaan Structure Therapeutics Inc GPCR|MDXG - Volume dodolan mangsa ngarep perusahaan|rezolutebio.com - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Lexicon Pharmaceuticals|MBX (MBX Biosciences Inc) - Volume dodolan mangsa ngarep perusahaan|ALT - Dodolan mangsa ngarep perusahaan|AARD (Aardvark Therapeutics Corp) - Prakiraan volume dodolan|Sagimet Biosciences, Inc. (SGMT) - Dodolan mangsa ngarep perusahaan|Prakiraan volume dodolan BIOA|BMEA - Volume dodolan sing dikarepake perusahaan|Prakiraan volume dodolan QNCX (Quince Therapeutics, Inc.)|fractyl.com (GUTS) - Volume dodolan sing dikarepake perusahaan|vTv Therapeutics Inc - Prakiraan volume dodolan|ATPC - Prakiraan volume dodolan|Pluri Inc. (PLUR) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Synlogic, Inc.|Volume dodolan mangsa ngarep perusahaan LPCN|Prakiraan pendapatan perusahaan MTNB|Prakiraan pendapatan perusahaan sprucebiosciences.com (SPRB)|Galecto - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Carmell Corp CTCX|LUMO - Volume dodolan mangsa ngarep perusahaan|ONVO - Prakiraan pendapatan perusahaan|radiuspharm.com (RDUS) - Volume dodolan mangsa ngarep perusahaan